Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Christoph U. Correll, MD, has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of Cardio Diagnostics, Mindpax, and LB Pharma.
Robert O. Cotes, MD
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Robert O. Cotes, MD: consultant/advisor/speaker: Saladax; researcher: Alkermes, Karuna, Otsuka, Roche.
Jonathan M. Meyer, MD
Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California
Jonathan Meyer, MD: consultant/advisor/speaker: Alkermes, AbbVie, Axsome, Bioexcel, Cervel, ITCI, Karuna, Neurocrine, Otsuka, Relmada, Sunovion, Teva.